Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- sPLA-2 Escherichia P-14555
- Product Overview:
Secretory phospholipase A2 (sPLA2) (Type IIA) is a calcium-dependent PLA2 superfamily member that is encoded by PLA2G2A in humans.{56210} It is composed of a highly-conserved calcium-binding loop, a catalytic domain, sPLA2 Type I- and II-specific disulfides that provide stability, and a C-terminal extension but lacks the N-terminal signal peptide found in sPLA2 (Type IB) and sPLA2 (Type X). sPLA2 (Type IIA) is expressed in platelets, synovial fluid, vascular smooth muscle cells, adipose tissue, the liver, and the gut.{65319,4588} sPLA2 (Type IIA) functions in a cell- and tissue type-specific manner, preferentially hydrolyzing bacterial membrane phosphatidylglycerol (PG) and phosphatidylethanolamine (PE) as a mechanism of host defense. sPLA2 (Type IIA) is upregulated at sites of acute and chronic inflammation where it generates lysophosphatidic acid and arachidonic acid, which is further metabolized to inflammatory lipid mediators and a variety of eicosanoid autocrine and paracrine signaling molecules.{65320} Plasma levels of sPLA2 (Type IIA) are associated with the presence of sepsis and are increased in patients with rheumatoid arthritis, acute coronary syndrome, asthma, or inflammatory bowel disease (IBD). Cayman’s sPLA2 (human, recombinant Type IIA) protein contains an asparagine to alanine substitution at position 1 to ensure proper removal of the N-terminal methionine during protein expression. Cayman’s sPLA2 (human, recombinant Type IIA) can be used for enzyme activity assays. The specific activity of Cayman’s sPLA2 (human, recombinant Type IIA) was established using Cayman’s sPLA2 Assay Kit (Item No. 765001) with 1.48 mM 1,2-bis(heptanoylthio) glycerophosphocholine (Item No. 62235) as the substrate.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.